tetano
Editor, Senior Moderator
Cells
. 2022 Oct 24;11(21):3355.
doi: 10.3390/cells11213355.
Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
Qianling Su[SUP] 1 [/SUP], Wei Shi[SUP] 1 [/SUP], Xianing Huang[SUP] 1 [/SUP], Yakun Wan[SUP] 2 [/SUP], Guanghui Li[SUP] 2 [/SUP], Bengang Xing[SUP] 3 [/SUP], Zhi Ping Xu[SUP] 4 [/SUP], Hongbo Liu[SUP] 5 [/SUP], Bruce D Hammock[SUP] 6 [/SUP], Xiaomei Yang[SUP] 1 [/SUP], Shihua Yin[SUP] 1 [/SUP], Xiaoling Lu[SUP] 1 [/SUP]
Affiliations
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health. This study screened and yielded specific nanobodies (Nbs) against SARS-CoV-2 spike protein receptor binding domain (RBD), following testing its basic characteristics. A nanobody phage library was established by immunizing a camel with RBD protein. After three rounds of panning, the positive colonies were screened by enzyme-linked immunosorbent assay (ELISA). By sequencing, four different sequences of nanobody gene fragments were selected. The four nanobody fusion proteins were expressed and purified, respectively. The specificity and affinity of the four nanobodies were identified by ELISA. Our results showed that an immune phage display library against SARS-CoV-2 has been successfully constructed with a library capacity of which was 4.7 × 10[SUP]8[/SUP] CFU. The four purified nanobodies showed specific high-affinity binding SARS-CoV-2 S-RBD. Among these, the antigen binding affinity of Nb61 was more comparable to that of commercial rabbit anti-SARS-CoV-2 S-RBD antibodies. In sum, our study has obtained four nanobody strains against SARS-CoV-2 S-RBD with significant affinity and specificity, therefore laying an essential foundation for further research as well as the applications of diagnostic and therapeutic tools of SARS-CoV-2.
Keywords: SARS-CoV-2; nanobody; phage display; single-domain antibody; spike protein.
. 2022 Oct 24;11(21):3355.
doi: 10.3390/cells11213355.
Screening, Expression, and Identification of Nanobody against SARS-CoV-2 Spike Protein
Qianling Su[SUP] 1 [/SUP], Wei Shi[SUP] 1 [/SUP], Xianing Huang[SUP] 1 [/SUP], Yakun Wan[SUP] 2 [/SUP], Guanghui Li[SUP] 2 [/SUP], Bengang Xing[SUP] 3 [/SUP], Zhi Ping Xu[SUP] 4 [/SUP], Hongbo Liu[SUP] 5 [/SUP], Bruce D Hammock[SUP] 6 [/SUP], Xiaomei Yang[SUP] 1 [/SUP], Shihua Yin[SUP] 1 [/SUP], Xiaoling Lu[SUP] 1 [/SUP]
Affiliations
- PMID: 36359751
- DOI: 10.3390/cells11213355
Abstract
Coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), an infectious disease that has become a serious burden on global public health. This study screened and yielded specific nanobodies (Nbs) against SARS-CoV-2 spike protein receptor binding domain (RBD), following testing its basic characteristics. A nanobody phage library was established by immunizing a camel with RBD protein. After three rounds of panning, the positive colonies were screened by enzyme-linked immunosorbent assay (ELISA). By sequencing, four different sequences of nanobody gene fragments were selected. The four nanobody fusion proteins were expressed and purified, respectively. The specificity and affinity of the four nanobodies were identified by ELISA. Our results showed that an immune phage display library against SARS-CoV-2 has been successfully constructed with a library capacity of which was 4.7 × 10[SUP]8[/SUP] CFU. The four purified nanobodies showed specific high-affinity binding SARS-CoV-2 S-RBD. Among these, the antigen binding affinity of Nb61 was more comparable to that of commercial rabbit anti-SARS-CoV-2 S-RBD antibodies. In sum, our study has obtained four nanobody strains against SARS-CoV-2 S-RBD with significant affinity and specificity, therefore laying an essential foundation for further research as well as the applications of diagnostic and therapeutic tools of SARS-CoV-2.
Keywords: SARS-CoV-2; nanobody; phage display; single-domain antibody; spike protein.